Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028677 · ClinicalTrials.gov registry record · NA
Oxytocin Treatment of Schizophrenia
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT01028677 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 17 participants.
The verdict
NCT01028677, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia. Participants: Up to 80 adults with schizophrenia for at least one year and with a high rating for paranoia. Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal spray (6 insufflations/dose or 24 IU) for 6 weeks. Before, during and at the end of the trial, each subject will undergo social cognitive measures (primary outcomes) and psychiatric symptom ratings (secondary outcomes).
Interventions
- DRUG intranasal spray with oxytocin
- OTHER nasal spray without oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028677
The ClinicalTrials.gov registry entry for NCT01028677 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which intranasal spray with oxytocin is the first listed.
NCT01028677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028677 about?
NCT01028677 is a clinical study titled "Oxytocin Treatment of Schizophrenia". Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia. Participants: Up to 80 adults with schizophrenia for at least one year and with a high rating for parano...
What is the current status of trial NCT01028677?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2009-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01028677?
The interventions under investigation include: intranasal spray with oxytocin (DRUG), nasal spray without oxytocin (OTHER).
Who is sponsoring clinical trial NCT01028677?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.